Real-world data of long-term survival in patients with T-cell lymphoma who underwent stem cell transplantation
Dong Won Baek, Joon Ho Moon, Jae Hoon Lee, Ka‐Won Kang, Ho Sup Lee, Hyeon‐Seok Eom, E. Lee, Ji Hyun Lee, Jeong‐Ok Lee, Seong Kyu Park, Seok Jin Kim, Keon Hee Yoo, Sung‐Soo Yoon, Young‐Il Koh, Hyoung Jin Kang, Jong-Ho Won, Chuhl Joo Lyu, Seung Min Hahn, Jung‐Hee Lee, Joon Seong Park, Jae‐Cheol Jo, Yeung‐Chul Mun, Deok‐Hwan Yang, Ga‐Young Song, Sung-Nam Lim, Sang Kyun Sohn, The Korean Society of Blood and Marrow Transplantation
Abstract
This study aimed to identify the benefits of autologous-stem cell transplantation (auto-SCT) and allogeneic-SCT (allo-SCT) in patients with aggressive T-cell lymphomas to aid in the selection of transplantation type in clinical practice. This study retrospectively analyzed data from 598 patients who underwent transplantation for T-cell lymphomas from 2010 to 2020. In total, 317 patients underwent up-front SCT as consolidation therapy. The 3-year progression-free survival (PFS) and overall survival (OS) were 68.7% and 76.1%, respectively. Patients who underwent auto-SCT had significantly better OS (p = 0.026) than those who underwent allo-SCT; however, no statistical difference in PFS was found. Transplantation was used as a salvage therapy in 188 patients who had relapsed/refractory disease. Overall, 96 (51.1%) patients underwent auto-SCT and 92 (48.9%) patients underwent allo-SCT. Auto-SCT improved long-term survival in patients with complete remission (CR). Allo-SCT demonstrated better 3-year PFS in patients with partial remission and relapsed/refractory disease status. However, >50% of patients died within 1 year of allo-SCT. As a consolidative therapy, up-front auto-SCT demonstrated a survival benefit. Auto-SCT was also effective in patients who achieved CR after salvage therapy. If the disease persists or cannot be controlled, allo-SCT may be considered with reduced intensity conditioning.